Literature DB >> 31440820

Full-field electroretinogram behavior in Vogt-Koyanagi-Harada disease: a 24-month longitudinal study in patients from acute onset evaluated with multimodal analysis.

Viviane Mayumi Sakata1,2, Marcelo Mendes Lavezzo3, Felipe T da Silva4, Ever Ernesto Caso Rodriguez3, Celso Morita3, Smairah Frutuoso Abdallah3, Maria Kiyoko Oyamada3, Carlos Eduardo Hirata3, Joyce Hisae Yamamoto3.   

Abstract

PURPOSE: To prospectively evaluate the dynamic changes of the full-field electroretinogram (ff-ERG) and its association with inflammatory signs in patients with Vogt-Koyanagi-Harada disease (VKHD) followed up after acute onset.
METHODS: Twelve acute VKHD patients, who were followed up for at least 24 months, were enrolled at a tertiary center from June 2011 to January 2017. Treatment consisted of intravenous methylprednisolone followed by 1 mg/kg/day of oral prednisone with a slow tapering associated with late non-steroidal immunosuppressive therapy in previously defined cases. Inflammation was systematically evaluated with clinical and posterior segment imaging (PSI) exams (fluorescein angiography, FA, indocyanine green angiography, ICGA, enhanced depth imaging optical coherence tomography, EDI-OCT). A ff-ERG was performed upon enrollment as well as at predefined intervals. Scotopic ff-ERG parameters changes between the 12th and 24th months defined the ERG-stable or ERG-worsening groups. "Flare" was defined as an appearance or worsening of inflammatory signs (after the initial 6 months following disease onset) under the predefined treatment protocol.
RESULTS: ff-ERG parameters initially improved in all eyes; in the evaluation between the 12th and 24th months, ff-ERG results were stable in 17 eyes (71 %) and worsened in 7 eyes (29 %). Subnormal ff-ERG results were observed in 15 eyes (62 %) at the 24th month. On the other hand, the flare was observed in 8 eyes (33 %) as cells in the anterior chamber and in 24 eyes (100 %) as any PSI inflammatory sign. The ERG-worsening group presented thicker subfoveal choroid at the first month (p = 0.001) and fluctuations in choroidal thickness more often during follow-up when compared to the ERG-stable group (p = 0.02).
CONCLUSIONS: Scotopic ff-ERG parameters worsened between the 12th and 24th months in a quarter of the patients. Subclinical inflammation detected as an increase in CT seems to be related to worsening in visual function measured with ffERG.

Entities:  

Keywords:  Corticosteroid; Electroretinogram; Indocyanine green angiography; Subclinical inflammation; Vogt-Koyanagi-Harada

Mesh:

Year:  2019        PMID: 31440820     DOI: 10.1007/s00417-019-04440-w

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  30 in total

1.  Associations among visual acuity and vision- and health-related quality of life among patients in the multicenter uveitis steroid treatment trial.

Authors:  Kevin D Frick; Lea T Drye; John H Kempen; James P Dunn; Gary N Holland; Paul Latkany; Narsing A Rao; H Nida Sen; Elizabeth A Sugar; Jennifer E Thorne; Robert C Wang; Janet T Holbrook
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-03-09       Impact factor: 4.799

2.  Retinal functional changes measured by microperimetry after immunosuppressive therapy in patients with Vogt-Koyanagi-Harada disease.

Authors:  Ahmed M Abu El-Asrar; Hani S Al-Mezaine; Suhail Hemachandran; Rajab Hariz; Dustan Kangave
Journal:  Eur J Ophthalmol       Date:  2012 May-Jun       Impact factor: 2.597

3.  Visual function in Vogt-Koyanagi-Harada patients.

Authors:  Soon-Phaik Chee; Chi D Luu; Ching-Li Cheng; Wee-Kiak Lim; Aliza Jap
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-11       Impact factor: 3.117

4.  Longitudinal Study of Visual Function in Vogt-Koyanagi-Harada Disease Using Full-Field Electroretinography.

Authors:  Wen Yuan; Chunjiang Zhou; Qingfeng Cao; Ziyu Du; Rong Hu; Yao Wang; Aize Kijlstra; Peizeng Yang
Journal:  Am J Ophthalmol       Date:  2018-04-25       Impact factor: 5.258

5.  Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome.

Authors:  P E Rubsamen; J D Gass
Journal:  Arch Ophthalmol       Date:  1991-05

6.  A clinical grading system based on ultra-wide field retinal imaging for sunset glow fundus in Vogt-Koyanagi-Harada disease.

Authors:  Eun Kyoung Lee; Sang-Yoon Lee; Hyeong Gon Yu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-15       Impact factor: 3.117

7.  Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease.

Authors:  Tatsushi Kawaguchi; Shintaro Horie; Nadia Bouchenaki; Kyoko Ohno-Matsui; Manabu Mochizuki; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2009-01-17       Impact factor: 2.031

Review 8.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

9.  Alterations of color vision and central visual field in patients with Vogt-Koyanagi-Harada syndrome.

Authors:  Peizeng Yang; Min Sun; Xiaoli Liu; Hongyan Zhou; Wang Fang; Li Wang; Aize Kijlstra
Journal:  J Ophthalmic Inflamm Infect       Date:  2012-02-02

Review 10.  Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.

Authors:  Carl P Herbort; Ahmed M Abu El Asrar; Joyce H Yamamoto; Carlos E Pavésio; Vishali Gupta; Moncef Khairallah; Ilknur Tugal-Tutkun; Masoud Soheilian; Masuru Takeuchi; Marina Papadia
Journal:  Int Ophthalmol       Date:  2016-11-14       Impact factor: 2.031

View more
  1 in total

Review 1.  Advances and potential new developments in imaging techniques for posterior uveitis Part 2: invasive imaging methods.

Authors:  Carl P Herbort; Ilknur Tugal-Tutkun; Alessandro Mantovani; Piergiorgio Neri; Moncef Khairallah; Ioannis Papasavvas
Journal:  Eye (Lond)       Date:  2020-08-10       Impact factor: 3.775

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.